T-cell adoptive immunotherapy for acute lymphoblastic leukemia
Autor: | Terry J. Fry, Crystal L. Mackall |
---|---|
Rok vydání: | 2013 |
Předmět: |
Adult
Male Adoptive cell transfer Sialic Acid Binding Ig-like Lectin 2 T-Lymphocytes T cell Antigens CD19 Receptors Antigen T-Cell Article CD19 Antigen Recurrence Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Acute lymphocytic leukemia Humans Medicine biology business.industry Cancer Hematology medicine.disease Adoptive Transfer Chimeric antigen receptor Leukemia medicine.anatomical_structure Cancer research biology.protein Female Genetic Engineering business |
Zdroj: | Hematology Am Soc Hematol Educ Program |
ISSN: | 1520-4383 1520-4391 |
Popis: | Substantial progress has been made in the treatment of precursor B-cell acute lymphoblastic leukemia (B-ALL), but recurrent disease remains a leading cause of death in children due to cancer and outcomes for adults with B-ALL remain poor. Recently, complete clinical responses have been observed in small numbers of patients with B-ALL treated with adoptive immunotherapy using T cells genetically engineered to express chimeric antigen receptors (CARs) targeting CD19, a cell surface molecule present in essentially all cases of B-ALL. Preclinical data suggest that CARs targeting CD22, another antigen present in the majority of B-ALL cases, are similarly potent. Several clinical studies already under way will soon more clearly define the rate of response to this novel therapy in B-ALL. Further work is needed to identify optimal platforms for CAR-based adoptive immunotherapy for leukemia, to establish guidelines for managing toxicity, and to determine whether the remissions induced by this approach can be rendered durable. |
Databáze: | OpenAIRE |
Externí odkaz: |